Recipient–donor chimerism is routinely analyzed after allogeneic hematopoietic stem cell
transplantation (HSCT) to monitor engraftment and graft rejection. For malignancies …

Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic
hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate …

The role of chimerism analysis as a prognostic indicator of relapse after hematopoietic stem
cell transplantation (SCT) is controversial. We monitored chimerism status by short tandem …

OBJECTIVE: Chimerism is well-established for surveillance of acute myeloid leukemia
(AML) patients after allogeneic hematopoietic stem cell transplantation (HSCT), but …

Chimerism analysis after allogeneic hematopoietic stem cell transplantation (AHSCT)
unveils the conversion of recipient's hematopoiesis to donor type and is useful for detection …

Increasing mixed chimerism (MC) after allogeneic stem cell transplantation (SCT) has been
associated with a high risk of relapse in acute leukemia. We evaluated a new method for …

Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in
patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) …

Increasing mixed chimerism (reemerging recipient cells) after allogeneic hematopoietic cell
transplant (allo-HCT) can indicate relapse, the leading factor determining mortality in blood …

Donor T cell chimerism is associated with relapse outcomes after allogeneic stem cell
transplantation (alloSCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes …

In acute myeloid leukemia (AML), the selection of poor‐risk patients for allogeneic
hematopoietic stem cell transplantation (HSCT) is associated with rather high post …